According to a report on Thursday by Bloomberg, Makan Delrahim, Assistant Attorney General (AAG) for the Department of Justice’s Antitrust Division, outlined some of the obstacles the government faces in bringing antitrust cases against big technology companies.
“Just because somebody is big does not mean they have violated the laws. Nor should we condemn them because they have succeeded,” Delrahim said at the Fordham Conference in New York. Delrahim was responding to a question from an audience member who asked about targeting Amazon as a monopoly and breaking up the online retailer.
“Is any of their conduct in any way limiting the ability of that upstart to challenge their market position in that market where they’re dominating?” Delrahim said. “Big is not bad but behaving badly is bad.”
In his remarks Thursday, Delrahim also spoke of what he has achieved in his first year as AAG.
“In my year as AAG, we have undertaken several initiatives aimed at reinventing our policies for the better. For example, the Division convened a series of public roundtables at which participants from all sides weighed in on issues of regulatory reform, including the issue of anticompetitive regulations. We have also embarked on a project to terminate over one thousand outdated consent decrees, which have for years remained on our court’s dockets, and in some cases, even created anticompetitive market conditions.”
Full Content: Department of Justice
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas